No matches
Dermatology

KOL Video Interview – Dr Paula Luna

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
Paula Luna, MD
MD
Paula Luna

Related resources

On the Surface: Restoring the Skin Barrier in Patients With AD

On the Surface: Restoring the Skin Barrier in Patients With AD

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

expert video
The Impact of Skin Dysbiosis on Atopic Dermatitis

The Impact of Skin Dysbiosis on Atopic Dermatitis

expert video
Association of Younger Age of Onset With Persistence of AD

Association of Younger Age of Onset With Persistence of AD

expert video
Can early intervention modify the course of AD?

Can early intervention modify the course of AD?

expert video
Guideline-Based Diagnosis of Atopic Dermatitis

Guideline-Based Diagnosis of Atopic Dermatitis

interactivity
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Podcast
Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

expert video
CSU is Unpredictable in its Course and Duration

CSU is Unpredictable in its Course and Duration

expert video
Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

expert video
The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

expert video
Can Early Intervention Shape the Course of Atopic Dermatitis?

Can Early Intervention Shape the Course of Atopic Dermatitis?

expert video
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

expert video
Real-World Effectiveness of Advanced Systemic Treatments in AD

Real-World Effectiveness of Advanced Systemic Treatments in AD

expert video
IL-4 Contributes to Systemic Type 2 Inflammation in AD

IL-4 Contributes to Systemic Type 2 Inflammation in AD

expert video
The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

expert video
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation
Prurigo Nodularis: The Patient Journey

Prurigo Nodularis: The Patient Journey

interactivity
UCARE 2023: CSU – The Brazil Perspective

UCARE 2023: CSU – The Brazil Perspective

expert video
The Burden of AD: More Than Skin Deep

The Burden of AD: More Than Skin Deep

Infographic
Most Burdensome Symptoms Rated by PN Patients

Most Burdensome Symptoms Rated by PN Patients

expert video
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

expert video
ADVENT On Air - Dermatology

ADVENT On Air | Expert Discussions in Dermatology

Podcast
The Pathophysiology of Prurigo Nodularis

The Pathophysiology of Prurigo Nodularis

videoanimation
The Role of Type 2 Inflammation in Multiple Disease Trajectories

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Infographic
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

expert video
UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

expert video
Guideline and Patient Management in CSU

Guideline and Patient Management in CSU

expert video
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

expert video
Emerging Data on Advanced Systemic Treatments for Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD

expert video
The Role of Type 2 Inflammation in Moderate-to-Severe AD

The Role of Type 2 Inflammation in Moderate-to-Severe AD

expert video
Type 2 Inflammation Within Skin Tissue in AD

Type 2 Inflammation Within Skin Tissue in AD

expert video
TBD

Prurigo Nodularis (PN): Understanding Its Clinical Features, Complex Burden, and Underlying Mechanisms

Infographic
Beyond Clinical Control: Targeting Type 2 Inflammation for Improved Patient Outcomes

Beyond Clinical Control: Targeting Type 2 Inflammation for Improved Patient Outcomes

expert video
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

expert video
UCARE 2023: Neuronal Involvement in CSU

UCARE 2023: Neuronal Involvement in CSU

expert video
Treatment Goals, Current and Emerging Therapies in CSU

Treatment Goals, Current and Emerging Therapies in CSU

expert video
Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

expert video
Early Intervention and the Potential for Disease Modification in Children With AD

Early Intervention and the Potential for Disease Modification in Children With AD

expert video
Early Intervention and the Potential For Disease Modification in AD

Early Intervention and the Potential For Disease Modification in AD

expert video
Epidemiology and Pathophysiology of AD in Children

Epidemiology and Pathophysiology of AD in Children

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?

The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?

expert video
Neuroimmune Axis in Atopic Dermatitis

Neuroimmune Axis in Atopic Dermatitis

expert video
UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

expert video
The Role of Chronic Inflammation in the Pathogenesis of CSU

The Role of Chronic Inflammation in the Pathogenesis of CSU

expert video

Learning objectives

  • Review the potential considerations when discussing the concept of disease modification in AD
  • Discuss the potential role of IgE as a biomarker for assessing subclinical control in pediatric patients with AD
Tags
pediatricexpert insightsmechanism of disease
MAT-GLB-2506237 - 1.0 - 11/2025

About this expert

Dermatology

Paula Luna

MD

The Hospital Aleman, Buenos Aires

See author’s profile
Paula Luna, MD

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: PeruChange country/region